QIAGEN Names Pratt CEO Amid Strategic Review
Event summary
- Jonathan M. Pratt appointed QIAGEN CEO effective September 1, 2026, succeeding Thierry Bernard.
- Pratt brings 25+ years of life sciences and lab tech leadership, most recently as Filtration Group CEO.
- Supervisory Board highlights Pratt's global industry knowledge and operational improvement track record.
- Thierry Bernard will support transition through year-end 2026.
- QIAGEN reaffirms 2026 financial outlook amid strategic review process.
The big picture
QIAGEN's CEO change comes as the company continues its strategic review, suggesting potential portfolio adjustments or operational realignment. Pratt's appointment reflects a focus on commercial execution and operational performance improvement, key challenges for diagnostic and life sciences companies facing margin pressures. His experience in similar-scale businesses (Filtration Group's $2.7B sale to Parker-Hannifin) suggests he may push for similar strategic moves at QIAGEN.
What we're watching
- Strategic Review Impact
- Whether QIAGEN's strategic review will lead to material changes in portfolio or structure under new leadership.
- Execution Risk
- How quickly Pratt can translate his operational improvement experience to QIAGEN's global business.
- Growth Priorities
- Which segments Pratt will prioritize given his background in analytical instruments and bioprocessing.